<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093795</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP B-38</org_study_id>
    <secondary_id>U10CA012027</secondary_id>
    <nct_id>NCT00093795</nct_id>
    <nct_alias>NCT00191958</nct_alias>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer</brief_title>
  <official_title>A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC→P); DD AC Followed By DD Paclitaxel Plus Gemcitabine (DD AC→PG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide,
      paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they
      stop growing or die. Giving combination chemotherapy after surgery may kill any remaining
      tumor cells.

      PURPOSE: This randomized phase III trial is studying three different combination chemotherapy
      regimens and comparing how well they work in treating women who have undergone surgery for
      node-positive breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare disease-free survival in women with node-positive breast cancer treated with 3
           different adjuvant chemotherapy regimens comprising dose-dense doxorubicin,
           cyclophosphamide, paclitaxel, and gemcitabine vs docetaxel, doxorubicin, and
           cyclophosphamide vs dose-dense doxorubicin, cyclophosphamide, and paclitaxel.

      Secondary

        -  Compare overall survival, recurrence-free interval, and distant recurrence-free
           interval, in patients treated with these regimens.

        -  Compare the toxic effects of these regimens in these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to number
      of positive lymph nodes (1-3 vs 4-9 vs ≥ 10), hormone receptor status (estrogen receptor
      [ER]- and progesterone receptor [PgR]- negative vs ER- and/or PgR-positive), type of prior
      surgery and planned radiotherapy (lumpectomy and local radiotherapy [RT] without regional RT
      vs lumpectomy and local RT with regional RT vs mastectomy without RT vs mastectomy with local
      or regional RT). Patients are randomized to 1 of 3 treatment arms.

        -  Group 1: Patients receive doxorubicin IV over 15 minutes, cyclophosphamide IV over 30
           minutes, and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 6
           courses.

        -  Group 2: Patients receive AC chemotherapy comprising doxorubicin IV over 15 minutes and
           cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 14 days for 4
           courses. Beginning 14 days after the last dose of AC, patients receive paclitaxel IV
           over 3 hours on day 1. Treatment repeats every 14 days for 4 courses.

        -  Group 3: Patients receive AC chemotherapy as in Group 2. Beginning 14 days after the
           last dose of AC, patients receive paclitaxel as in Group 2 and gemcitabine IV over 30-60
           minutes on day 1. Treatment repeats every 14 days for 4 courses.

      In all arms, treatment continues in the absence of disease progression or unacceptable
      toxicity.

      Beginning 3-12 weeks after the last dose of chemotherapy, patients with ER-positive and/or
      PgR-positive tumors receive hormonal therapy.

      Beginning no sooner than 3 weeks after the last dose of chemotherapy, patients treated with
      lumpectomy undergo whole-breast radiotherapy. Patients treated with mastectomy may undergo
      chest wall and/or regional nodal radiotherapy.

      Patients are followed every 6 months for 5 years and then annually thereafter.

      PROJECTED ACCRUAL: A total of 4,800 patients will be accrued for this study within 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer</measure>
    <time_frame>5 years</time_frame>
    <description>The percentage of patients alive and cancer-free.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of participants alive at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free Interval: Time to First Local, Regional, or Distant Recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patients recurrence-free (no first local, regional, or distant recurrence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Recurrence-free Interval: the Time to Distant Disease Recurrence Only</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patients distant recurrence-free (no distant disease recurrence only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>30 days after the last dose of study therapy (about 7 months after study entry)</time_frame>
    <description>Percentage of patients who ever experienced grade 2 or higher toxicities.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4894</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1: TAC X 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin, cyclophosphamide, and docetaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: AC X 4 then P X 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin, cyclophosphamide, and paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: AC X 4 then PG X 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles</description>
    <arm_group_label>Group 1: TAC X 6</arm_group_label>
    <arm_group_label>Group 2: AC X 4 then P X 4</arm_group_label>
    <arm_group_label>Group 3: AC X 4 then PG X 4</arm_group_label>
    <other_name>C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2 IV every 21 days for 6 cycles</description>
    <arm_group_label>Group 1: TAC X 6</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>2000 mg/m2 IV every 14 days for 4 cycles</description>
    <arm_group_label>Group 3: AC X 4 then PG X 4</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>G</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m2 IV every 14 days for 4 cycles</description>
    <arm_group_label>Group 2: AC X 4 then P X 4</arm_group_label>
    <arm_group_label>Group 3: AC X 4 then PG X 4</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
    <arm_group_label>Group 1: TAC X 6</arm_group_label>
    <arm_group_label>Group 2: AC X 4 then P X 4</arm_group_label>
    <arm_group_label>Group 3: AC X 4 then PG X 4</arm_group_label>
    <other_name>A</other_name>
    <other_name>Adriamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must consent to participate in the study and must have signed an approved
             consent form conforming with federal and institutional guidelines.

          -  The patient must have a life expectancy of at least 10 years and a Zubrod performance
             status of 0 or 1. (Comorbid conditions but not the diagnosis of breast cancer should
             be taken into consideration when determining life expectancy.)

          -  The interval between the last surgery for breast cancer staging or treatment and
             randomization must be no more than 84 days.

          -  The tumor must be invasive carcinoma of the breast on histologic examination.

          -  All of the following staging criteria must be met:

               -  By clinical and pathologic evaluation, primary tumor must be T1-3;

               -  By clinical evaluation, ipsilateral nodes must be cN0, cN1, or cN2a;

               -  By pathologic evaluation, ipsilateral nodes must be pN1 (pN1mi, pN1a, pN1b,
                  pN1c), pN2a, pN3a, or pN3b (only if due to microscopic involvement of internal
                  mammary node detected by sentinel lymph node dissection and with more than 3
                  positive axillary lymph nodes).

          -  Patients must have an estrogen receptor (ER) analysis performed on the primary tumor
             prior to randomization. If ER analysis is negative, then progesterone receptor (PgR)
             analysis must be performed. If ER analysis is positive, PgR analysis is desired, but
             not mandatory. (&quot;Marginal&quot; or &quot;borderline&quot; results [i.e., those not definitely
             negative] will be considered positive regardless of the methodology used.)

          -  Patients must have had either a lumpectomy or a total mastectomy. Patients must have
             completed one of the following procedures for evaluation of pathologic nodal status.

               -  Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph
                  nodes (This approach is strongly recommended.)

               -  Sentinel lymphadenectomy alone if one of the following criteria is met:

               -  Pathologic nodal staging based on sentinel lymphadenectomy is pN1mi or pN1b

               -  Surgeon elects not to remove additional non-sentinel nodes (This approach is
                  strongly discouraged, but will not preclude participation in B-38.)

               -  Axillary lymphadenectomy without sentinel node isolation procedure.

          -  Patients must have no clinical or radiologic evidence of metastatic disease.

          -  Patients with either skeletal pain or alkaline phosphatase that is greater than ULN
             but less than or equal to 2.5 x ULN are eligible for inclusion in the study if bone
             scans fail to demonstrate metastatic disease. Suspicious findings on bone scan must be
             confirmed as benign by x-ray, MRI, or biopsy.

          -  Patients with aspartate transaminase (AST) or alkaline phosphatase greater than ULN
             are eligible for inclusion in the study if liver imaging fails to demonstrate
             metastatic disease and the following requirements are met at the time of
             randomization.

               -  Postoperative absolute granulocyte count (AGC) must be greater than or equal to
                  1200/mm3.

               -  Postoperative platelet count must be greater than or equal to 100,000/mm3.

               -  The following criteria for postoperative evidence of adequate hepatic function
                  must be met:

                    -  total bilirubin must be less than or equal to ULN for the lab unless the
                       patient has a grade 1 bilirubin elevation (greater than ULN to 1.5 x ULN)
                       due to Gilbert's disease or similar syndrome due to slow conjugation of
                       bilirubin; and

                    -  alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab;
                       and

                    -  the AST must be less than or equal to 1.5 x ULN for the lab; and

                    -  alkaline phosphatase and AST cannot both be greater than ULN.

               -  Postoperative serum creatinine must be less than or equal to ULN.

          -  At the time of randomization, the patient must have had the following: history and
             physical exam, EKG, and imaging of the chest within the past 3 months and bilateral
             mammogram within the past 6 months.

          -  Within 3 months prior to entry, the patient must have a baseline left ventricular
             ejection fraction (LVEF), measured by Multiple Gated Acquisition (MUGA) scan or
             echocardiogram, greater than or equal to lower limit of normal (LLN) for the facility
             performing the procedure and no evidence of regional wall abnormalities.

          -  Patients with a history of non-breast malignancies are eligible if they have been
             disease-free for 5 or more years prior to randomization and are deemed by their
             physician to be at low risk for recurrence. Patients with the following cancers are
             eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the
             cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous
             cell carcinoma of the skin.

          -  Special conditions for eligibility of lumpectomy patients: radiation therapy and
             surgery. Patients treated by lumpectomy must meet all the eligibility criteria in
             addition to the following:

               -  Generally, lumpectomy should be reserved for tumors less than 5 cm. However, at
                  the investigator's discretion, patients treated with lumpectomy for tumors
                  greater than or equal to 5 cm are eligible if eligibility criteria for lumpectomy
                  are met.

               -  The margins of the resected specimen must be histologically free of invasive
                  tumor and DCIS as determined by the local pathologist. In patients for whom
                  pathologic examination demonstrates tumor present at the line of resection,
                  additional operative procedures may be performed to obtain clear margins. This is
                  permissible even if axillary evaluation has been completed. Patients in whom
                  tumor is still present at the resected margin after re-excision(s) must undergo
                  total mastectomy to be eligible. (Patients with margins positive for lobular
                  carcinoma in situ (LCIS) are eligible without additional resection.)

               -  Irradiation of regional lymph nodes is optional, but plans for radiation therapy
                  must be declared by the investigator prior to randomization for stratification
                  purposes.

          -  Special conditions for eligibility of mastectomy patients: radiation therapy o
             Postmastectomy chest wall and/or regional nodal irradiation is optional. Plans for
             radiation in mastectomy patients must be declared by the investigator prior to
             randomization for stratification purposes.

        Ineligibility Criteria

          -  Male patients are not eligible for this study. Women with one or more of the following
             conditions or prior therapies are also ineligible for this study:

          -  Tumor that has been determined to be human epidermal growth factor receptor 2
             (HER2)-positive by immunohistochemistry (3+) or by fluorescent in situ hybridization
             (positive for gene amplification).

          -  Contralateral breast cancer (invasive or DCIS) or a mass or mammographic abnormality
             in the opposite breast suspicious for malignancy unless there is biopsy proof that the
             mass is not malignant.

          -  Primary tumor staged as T4 for any reason.

          -  Clinical nodal stages including cN2b and cN3 or pathologic nodal stages including
             pN0(i+), pN2b, pN3b with clinically apparent internal mammary nodes, or pN3c.

          -  Suspicious nodes in the contralateral axilla or suspicious supraclavicular nodes.
             Patients with these conditions are considered ineligible unless there is biopsy
             evidence that these are not involved with tumor.

          -  Prior history of breast cancer, including DCIS (patients with a history of LCIS are
             eligible).

          -  Treatment, including radiation therapy, chemotherapy, and/or hormonal therapy
             administered for the currently diagnosed breast cancer prior to randomization. One
             exception is hormonal therapy, which may have been given for up to a total of 28 days
             anytime after diagnosis and before study entry. In such a case, hormonal therapy must
             stop at or before randomization and be re-started, if indicated, following
             chemotherapy. A second exception is radiation therapy for patients enrolled in NSABP
             B-39 and assigned to partial breast irradiation (Group 2). These patients may have
             received RT prior to B-38 study entry.

          -  Prior therapy with anthracyclines or taxanes for any malignancy.

          -  Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement
             therapy, etc. (These patients are eligible if this therapy is discontinued prior to
             randomization.)

          -  Therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, or other
             selective estrogen-receptor modulators (SERMs), either for osteoporosis or breast
             cancer prevention. (Patients are eligible only if these medications are discontinued
             prior to randomization.

          -  Cardiac disease that would preclude the use of anthracyclines. This includes:

               -  history of myocardial infarction documented by elevated cardiac enzymes or
                  regional wall abnormalities on assessment of left ventricular (LV) function;

               -  angina pectoris that requires the use of anti-anginal medication;

               -  any history of documented congestive heart failure;

               -  serious cardiac arrhythmia requiring medication;

               -  severe conduction abnormality;

               -  valvular disease with documented cardiac function compromise; and

               -  uncontrolled hypertension defined as blood pressure greater than 160/100 on
                  antihypertensive therapy.

          -  Conditions that would prohibit administration of corticosteroids.

          -  Sensory/motor neuropathy greater than or equal to grade 2, as defined by the NCI's
             Common Terminology Criteria for Adverse Events Version 3.0.

          -  Non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would
             preclude a patient from receiving any of the treatment options or would prevent
             prolonged follow-up.

          -  History of hepatitis B or C.

          -  Pregnancy or lactation at the time of proposed randomization. Women of reproductive
             potential must agree to use an effective non-hormonal method of contraception.

          -  Concurrent treatment with other investigational agents for the treatment of breast
             cancer.

          -  Psychiatric or addictive disorders or other conditions that, in the opinion of the
             investigator, would preclude the patient from meeting the study requirements.

          -  Special conditions for ineligibility of lumpectomy patients: radiation therapy and
             surgery

               -  For patients treated by lumpectomy, whole breast irradiation is required.

               -  The following patients will be ineligible:

               -  Patients with diffuse tumors (as demonstrated on mammography) treated with
                  lumpectomy. (These patients are eligible if they undergo mastectomy.)

               -  Patients treated with lumpectomy in whom there is another clinically dominant
                  mass or mammographically suspicious abnormality within the ipsilateral breast
                  remnant. Such a mass must be biopsied and demonstrated to be histologically
                  benign prior to randomization or, if malignant, must be surgically removed with
                  clear margins.

               -  Patients in whom the margins of the resected specimen are involved with invasive
                  tumor or DCIS.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert and Carol Weissman Cancer Center at Martin Memorial</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Shore Hospital</name>
      <address>
        <city>South Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Estabrook Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern New Jersey</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Cancer Center at Altru Hospital</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Oncology Group at Cleveland Clinic Cancer Center</name>
      <address>
        <city>Independence</city>
        <state>Ohio</state>
        <zip>44131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chestnut Hill Healthcare Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center - Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Ireland</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <results_first_submitted>November 13, 2017</results_first_submitted>
  <results_first_submitted_qc>November 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2017</results_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: TAC X 6</title>
          <description>Doxorubicin, cyclophosphamide, and docetaxel.
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
        </group>
        <group group_id="P2">
          <title>Group 2: AC X 4 Then P X 4</title>
          <description>Doxorubicin, cyclophosphamide, and paclitaxel
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
        </group>
        <group group_id="P3">
          <title>Group 3: AC X 4 Then PG X 4</title>
          <description>Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Gemcitabine: 2000 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1630"/>
                <participants group_id="P2" count="1634"/>
                <participants group_id="P3" count="1630"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1610"/>
                <participants group_id="P2" count="1618"/>
                <participants group_id="P3" count="1613"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No follow up data</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TAC X 6</title>
          <description>Doxorubicin, cyclophosphamide, and docetaxel. Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
        </group>
        <group group_id="B2">
          <title>AC X 4 Then P X 4</title>
          <description>Doxorubicin, cyclophosphamide, and paclitaxel Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
        </group>
        <group group_id="B3">
          <title>AC X 4 Then PG X 4</title>
          <description>Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles Gemcitabine: 2000 mg/m2 IV every 14 days for 4 cycles Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1623"/>
            <count group_id="B2" value="1623"/>
            <count group_id="B3" value="1621"/>
            <count group_id="B4" value="4867"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="9.5"/>
                    <measurement group_id="B2" value="51" spread="9.5"/>
                    <measurement group_id="B3" value="51" spread="9.4"/>
                    <measurement group_id="B4" value="51" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1623"/>
                    <measurement group_id="B2" value="1623"/>
                    <measurement group_id="B3" value="1621"/>
                    <measurement group_id="B4" value="4867"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer</title>
        <description>The percentage of patients alive and cancer-free.</description>
        <time_frame>5 years</time_frame>
        <population>For Arm 1 there is no follow-up data for 20 participants; for Arm 2 there is no follow-up data for 16 participants; and for Arm 3 there is no follow-up data for 17 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: TAC X 6</title>
            <description>Doxorubicin, cyclophosphamide, and docetaxel.
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>Group 2: AC X 4 Then P X 4</title>
            <description>Doxorubicin, cyclophosphamide, and paclitaxel
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
          <group group_id="O3">
            <title>Group 3: AC X 4 Then PG X 4</title>
            <description>Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Gemcitabine: 2000 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer</title>
          <description>The percentage of patients alive and cancer-free.</description>
          <population>For Arm 1 there is no follow-up data for 20 participants; for Arm 2 there is no follow-up data for 16 participants; and for Arm 3 there is no follow-up data for 17 participants.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1610"/>
                <count group_id="O2" value="1618"/>
                <count group_id="O3" value="1613"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1" lower_limit="78.0" upper_limit="82.0"/>
                    <measurement group_id="O2" value="82.2" lower_limit="80.2" upper_limit="84.0"/>
                    <measurement group_id="O3" value="80.6" lower_limit="78.5" upper_limit="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Percentage of participants alive at 5 years</description>
        <time_frame>5 years</time_frame>
        <population>For Arm 1 there is no follow-up data for 13 participants; for Arm 2 there is no follow-up data for 10 participants; and for Arm 3 there is no follow-up data for 12 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: TAC X 6</title>
            <description>Doxorubicin, cyclophosphamide, and docetaxel.
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>Group 2: AC X 4 Then P X 4</title>
            <description>Doxorubicin, cyclophosphamide, and paclitaxel
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
          <group group_id="O3">
            <title>Group 3: AC X 4 Then PG X 4</title>
            <description>Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Gemcitabine: 2000 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Percentage of participants alive at 5 years</description>
          <population>For Arm 1 there is no follow-up data for 13 participants; for Arm 2 there is no follow-up data for 10 participants; and for Arm 3 there is no follow-up data for 12 participants.</population>
          <units>percentage of patients alive</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1617"/>
                <count group_id="O2" value="1624"/>
                <count group_id="O3" value="1618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" lower_limit="88.1" upper_limit="91.1"/>
                    <measurement group_id="O2" value="89.1" lower_limit="87.4" upper_limit="90.5"/>
                    <measurement group_id="O3" value="90.8" lower_limit="89.3" upper_limit="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence-free Interval: Time to First Local, Regional, or Distant Recurrence</title>
        <description>Percentage of patients recurrence-free (no first local, regional, or distant recurrence)</description>
        <time_frame>5 years</time_frame>
        <population>For Arm 1 there is no follow-up data for 20 participants; for Arm 2 there is no follow-up data for 16 participants; and for Arm 3 there is no follow-up data for 17 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: TAC X 6</title>
            <description>Doxorubicin, cyclophosphamide, and docetaxel.
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>Group 2: AC X 4 Then P X 4</title>
            <description>Doxorubicin, cyclophosphamide, and paclitaxel
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
          <group group_id="O3">
            <title>Group 3: AC X 4 Then PG X 4</title>
            <description>Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Gemcitabine: 2000 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence-free Interval: Time to First Local, Regional, or Distant Recurrence</title>
          <description>Percentage of patients recurrence-free (no first local, regional, or distant recurrence)</description>
          <population>For Arm 1 there is no follow-up data for 20 participants; for Arm 2 there is no follow-up data for 16 participants; and for Arm 3 there is no follow-up data for 17 participants.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1610"/>
                <count group_id="O2" value="1618"/>
                <count group_id="O3" value="1613"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1" lower_limit="83.2" upper_limit="86.9"/>
                    <measurement group_id="O2" value="86.2" lower_limit="84.3" upper_limit="87.9"/>
                    <measurement group_id="O3" value="84.8" lower_limit="82.8" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distant Recurrence-free Interval: the Time to Distant Disease Recurrence Only</title>
        <description>Percentage of patients distant recurrence-free (no distant disease recurrence only)</description>
        <time_frame>5 years</time_frame>
        <population>For Arm 1 there is no follow-up data for 20 participants; for Arm 2 there is no follow-up data for 16 participants; and for Arm 3 there is no follow-up data for 17 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: TAC X 6</title>
            <description>Doxorubicin, cyclophosphamide, and docetaxel.
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>Group 2: AC X 4 Then P X 4</title>
            <description>Doxorubicin, cyclophosphamide, and paclitaxel
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
          <group group_id="O3">
            <title>Group 3: AC X 4 Then PG X 4</title>
            <description>Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Gemcitabine: 2000 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Distant Recurrence-free Interval: the Time to Distant Disease Recurrence Only</title>
          <description>Percentage of patients distant recurrence-free (no distant disease recurrence only)</description>
          <population>For Arm 1 there is no follow-up data for 20 participants; for Arm 2 there is no follow-up data for 16 participants; and for Arm 3 there is no follow-up data for 17 participants.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1610"/>
                <count group_id="O2" value="1618"/>
                <count group_id="O3" value="1613"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6" lower_limit="84.7" upper_limit="88.2"/>
                    <measurement group_id="O2" value="87.4" lower_limit="85.6" upper_limit="89.0"/>
                    <measurement group_id="O3" value="86.6" lower_limit="84.7" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <description>Percentage of patients who ever experienced grade 2 or higher toxicities.</description>
        <time_frame>30 days after the last dose of study therapy (about 7 months after study entry)</time_frame>
        <population>For Arm 1 there is no follow-up data for 23 participants; for Arm 2 there is no follow-up data for 11 participants; and for Arm 3 there is not follow-up data for 18 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: TAC X 6</title>
            <description>Doxorubicin, cyclophosphamide, and docetaxel.
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>Group 2: AC X 4 Then P X 4</title>
            <description>Doxorubicin, cyclophosphamide, and paclitaxel
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
          <group group_id="O3">
            <title>Group 3: AC X 4 Then PG X 4</title>
            <description>Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles
Gemcitabine: 2000 mg/m2 IV every 14 days for 4 cycles
Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity</title>
          <description>Percentage of patients who ever experienced grade 2 or higher toxicities.</description>
          <population>For Arm 1 there is no follow-up data for 23 participants; for Arm 2 there is no follow-up data for 11 participants; and for Arm 3 there is not follow-up data for 18 participants.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1607"/>
                <count group_id="O2" value="1623"/>
                <count group_id="O3" value="1612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" lower_limit="80.8" upper_limit="84.5"/>
                    <measurement group_id="O2" value="87.5" lower_limit="85.8" upper_limit="89.0"/>
                    <measurement group_id="O3" value="88.4" lower_limit="86.7" upper_limit="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Participants at Risk includes any patient who submitted an AE form.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAC X 6</title>
          <description>TAC X 6</description>
        </group>
        <group group_id="E2">
          <title>AC X 4 Then P X 4</title>
          <description>AC X 4 then P X 4</description>
        </group>
        <group group_id="E3">
          <title>AC X 4 Then PG X 4</title>
          <description>AC X 4 then PG X 4</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="277" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="187" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Esophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Duodenal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Intra-abdominal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Gallbladder infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Postoperative hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased (ALT/SGPT)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased (AST/SGOT)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Muscle weakness left-sided</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1231" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="1322" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="1323" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="184" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="325" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="185" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="201" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="510" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="504" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="497" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="284" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="245" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="306" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="805" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="784" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="774" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased (ALT/SGPT)</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="267" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="484" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="446" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="536" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="512" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="188" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="484" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="428" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="1604"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="1601"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="1612"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="1604"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Department of Regulatory Affairs</name_or_title>
      <organization>NSABP Foundation, Inc</organization>
      <phone>412-339-5300</phone>
      <email>regulatory@nsabp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

